249 related articles for article (PubMed ID: 27866769)
21. Vaccine-Induced Th1-Type Response Protects against Invasive Group A
Rivera-Hernandez T; Rhyme MS; Cork AJ; Jones S; Segui-Perez C; Brunner L; Richter J; Petrovsky N; Lawrenz M; Goldblatt D; Collin N; Walker MJ
mBio; 2020 Mar; 11(2):. PubMed ID: 32156809
[TBL] [Abstract][Full Text] [Related]
22. Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.
Martin TL; Jee J; Kim E; Steiner HE; Cormet-Boyaka E; Boyaka PN
Vaccine; 2017 Apr; 35(18):2511-2519. PubMed ID: 28343781
[TBL] [Abstract][Full Text] [Related]
23. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
[TBL] [Abstract][Full Text] [Related]
24. Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination.
Trent A; Ulery BD; Black MJ; Barrett JC; Liang S; Kostenko Y; David NA; Tirrell MV
AAPS J; 2015 Mar; 17(2):380-8. PubMed ID: 25527256
[TBL] [Abstract][Full Text] [Related]
25. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines.
Middelberg AP; Rivera-Hernandez T; Wibowo N; Lua LH; Fan Y; Magor G; Chang C; Chuan YP; Good MF; Batzloff MR
Vaccine; 2011 Sep; 29(41):7154-62. PubMed ID: 21651936
[TBL] [Abstract][Full Text] [Related]
26. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
27. Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.
Pandey M; Powell J; Calcutt A; Zaman M; Phillips ZN; Ho MF; Batzloff MR; Good MF
Sci Rep; 2017 Oct; 7(1):13786. PubMed ID: 29062085
[TBL] [Abstract][Full Text] [Related]
28. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
[TBL] [Abstract][Full Text] [Related]
29. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice.
Okamoto S; Tamura Y; Terao Y; Hamada S; Kawabata S
Vaccine; 2005 Sep; 23(40):4852-9. PubMed ID: 15990202
[TBL] [Abstract][Full Text] [Related]
30. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
31. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses.
Guerrero RA; Ball JM; Krater SS; Pacheco SE; Clements JD; Estes MK
J Virol; 2001 Oct; 75(20):9713-22. PubMed ID: 11559804
[TBL] [Abstract][Full Text] [Related]
32. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice.
Xue G; Yu L; Li S; Shen X
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):202-10. PubMed ID: 19912341
[TBL] [Abstract][Full Text] [Related]
33. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
34. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.
White JA; Blum JS; Hosken NA; Marshak JO; Duncan L; Zhu C; Norton EB; Clements JD; Koelle DM; Chen D; Weldon WC; Oberste MS; Lal M
Hum Vaccin Immunother; 2014; 10(12):3611-21. PubMed ID: 25483682
[TBL] [Abstract][Full Text] [Related]
35. Mucosal and systemic immunization with targeted fusion anti-caries DNA plasmid in young rats.
Liu GX; Xu QA; Jin J; Li YH; Jia R; Guo JH; Fan MW
Vaccine; 2009 May; 27(22):2940-7. PubMed ID: 19428904
[TBL] [Abstract][Full Text] [Related]
36. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
37. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.
Velasquez LS; Hjelm BE; Arntzen CJ; Herbst-Kralovetz MM
Clin Vaccine Immunol; 2010 Dec; 17(12):1850-8. PubMed ID: 20962211
[TBL] [Abstract][Full Text] [Related]
38. Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually.
Spinner JL; Oberoi HS; Yorgensen YM; Poirier DS; Burkhart DJ; Plante M; Evans JT
Vaccine; 2015 Oct; 33(43):5845-5853. PubMed ID: 26392012
[TBL] [Abstract][Full Text] [Related]
39. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.
Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Infect Immun; 2003 May; 71(5):2373-83. PubMed ID: 12704107
[TBL] [Abstract][Full Text] [Related]
40. Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8.
Campbell PT; Frost H; Smeesters PR; Kado J; Good MF; Batzloff M; Geard N; McVernon J; Steer A
Vaccine; 2018 Nov; 36(50):7618-7624. PubMed ID: 30401621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
